Genome-Scale CRISPR-Cas9 Analysis Reveals Tumor Heterogeneity and Identifies NDC80 as Novel Biomarker in HCC. Liu Z, Liu L, Liu S, Ba Y, et al. J Gastroenterol Hepatol 2025;40:2078-2090.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Liu Z, Liu L, Liu S, Ba Y, et al. Genome-Scale CRISPR-Cas9 Analysis Reveals Tumor Heterogeneity and Identifies NDC80 as Novel Biomarker in HCC. J Gastroenterol Hepatol 2025;40:2078-2090.
PMID: 40462261